{"id":"course-b1-vin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy regimen used in pediatric cancer treatment. Vincristine is a vinca alkaloid that binds to tubulin and prevents microtubule assembly, leading to cell cycle arrest and death. Course B1 typically refers to a standardized chemotherapy block in pediatric protocols (such as those for acute lymphoblastic leukemia), combining multiple cytotoxic agents to maximize tumor cell kill while managing resistance.","oneSentence":"Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:28.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric acute lymphoblastic leukemia (ALL)"},{"name":"Pediatric lymphomas and other hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Course B1 +Vin","genericName":"Course B1 +Vin","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric lymphomas and other hematologic malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}